In The News
April 9th, 2014 | Main Line Fertility is Recruiting Patients for the Eeva® aCGH Study
Main Line Fertility today began recruiting patients for the Eeva array-Comparative Genomic Hybridization (aCGH) Study.
“We are proud to be part of this Auxogyn sponsored clinical study utilizing the Eeva technology”, said Dr. Michael Glassner, “We are pleased to offer our patients the opportunity to participate in trials that can bring a deeper understanding of early embryo development to clinical practice.”
Eeva: The Early Embryo Viability Assessment Test, is an investigational test to be used by IVF laboratories to analyze early embryo development. At the heart of the Eeva System is software that was designed to assess critical differences in early embryo growth and determine an embryo’s viability and the potential for further development.
The Eeva Test was developed based on landmark research conducted at Stanford University1 which discovered that early embryo growth events can predict embryo development and reflect the underlying health of the embryo.
The goal of the Eeva aCGH Study is to collect imaging data on embryos followed to blastocyst stage (Day 5-6) and correlate Eeva parameters with array – Comparative Genomic Hybridization (aCGH) results and ongoing pregnancy rates.
If you are interested in participating in this research study, please contact Eileen Davies, Study Coordinator at (484) 380-4861 or firstname.lastname@example.org for more information.
Auxogyn hopes to change the field of reproductive health by translating scientific discoveries in early embryo development into clinical tools. For more information regarding Auxogyn and Eeva, please visit www.auxogyn.com and eevaivf.com.
Eeva is an investigational device. Limited by United States law to investigational use.
April 2nd, 2014 | Free Health Fair April 26th – Fertility Checkup
Main line Fertility will be participating in the Spring Into Action Health Fair at Club La Maison Health and Fitness Complex at 215 Sugartown Road, Wayne, PA on Saturday April 26th, 2014 from 10AM until 2PM. Free screenings and free demos.
November 12th, 2013 | Main Line Fertility featured on PHL17 at 6:19AM 11-12-13
Main Line Fertility was featured on PHL 17 Eye Opener on Tuesday November 12, 2013. PHL 17 interviewed Dr. Glassner about the Thrive IVF Study at Main Line Fertility. The video also features the Main Line Fertility IVF laboratory. For more information about studies, contact Eileen Davies at 484-380-4861
September 27th, 2013 | Dr. Michael Glassner featured on CBS TV show – “The Doctors” Oct 1, 2013
Dr. Michael Glassner and his patients – the Levys – were interviewed at Main Line Fertility for the CBS daytime TV show The Doctors. The Doctors featured a story about Connor Levy – the first baby in the world born after IVF and preimplantation genetic diagnosis (PGD) using the Next Generation DNA Sequencing (NGS) technique, which increases the chance of transferring an embryo that is most likely to implant, reduces miscarriage rate, and reduces the time and cost to achieve a healthy baby by reducing the number of repeat IVF cycles. Dr. Glassner flew to Los Angeles on August 22 for taping of the TV show. THE RISKS & REWARDS OF DECODING YOUR GENES aired Tuesday October 1st on “The Doctors” TV show.
For more information about NGS or NGS studies contact Dr. Sharon Anderson, PhD at email@example.com or 484-380-4884.
September 18th, 2013 | 2011 ART Pregnancy Statistics Released by SART
Society for Assisted Reproductive Technology (SART) recently released the 2011 pregnancy rates for IVF centers in the United States. Click below to see Main Line Fertility’s pregnancy rates for IVF, thawed embryos cycles, and donor egg cycles! Visit www.SART.org
August 23rd, 2013 | ABC Action News – featured Main Line Fertility and new IVF screening technique
Channel 6 ABC Action News lead the 5:30 newscast with the story about a new IVF screening test. The broadcast featured Main Line Fertility, Dr. Michael Glassner and his patients – the Levys. Connor Levy is the first baby in the world born after IVF and preimplantation genetic diagnosis (PGD) using the Next Generation DNA Sequencing (NGS) technique. NGS increases the chance of transferring an embryo that is most likely to implant, reduces miscarriage rate, and reduces the time and cost to achieve a healthy baby by reducing the number of repeat IVF cycles. For more information about NGS or NGS studies, contact Dr. Sharon Anderson, PhD at firstname.lastname@example.org or 484-380-4884